Guaifenesin

Company's First New Drug Approval 1 Addresses #1 Unmet Need for Long-Lasting Symptom Relief* Mucinex 12HR Cold & Fever Multi-Symptom is the first and only FDA-approved OTC cold and flu medication that treats fever, cough, chest congestion and body pain for 12 hours This marks the fourth FDA-approval for the Mucinex family of brands Mucinex 12HR Cold & Fever Multi-Symptom is now available at retailers nationwide NUTLEY, N.J., Aug. 5, 2026 /PRNewswire/ -- Reckitt announced today a milestone for the cold and flu category and the company: Mucinex® 12HR Cold & Fever Multi-Symptom is the first U.S. Food and Drug Administration (FDA)-approved over-the-counter (OTC) innovation in the cold and flu category in 14 years, and the first New Drug Application (NDA) under the Reckitt name to receive FDA approval.1 Developed to align with the way consumers choose to manage cold and flu symptoms, this achievement reflects more than a decade of Reckitt's scientific research, development, clinical evaluation and regulatory collaboration. Continue Reading Mucinex 12HR Cold & Fever Multi-Symptom is the first and only FDA-approved OTC cold and flu medication that treats fever, cough, chest congestion and body pain for 12 hours. Mucinex 12HR Cold & Fever Multi-Symptom is the first and only FDA-approved OTC cold and flu medication that treats fever, cough, chest congestion and body pain for 12 hours. Speed Speed The approval comes at a time when cold and flu place an increasingly significant burden on Americans, driving millions of illnesses, healthcare visits and missed days of work and school each year. According to The Centers for Disease Control and Prevention (CDC), the 2024-25 flu season resulted in an estimated 51 million illnesses, while the 2025-26 season saw a surge in flu cases across the country that coincided with an earlier flu season.2 As people continue to rely on OTC medicines as a first line of self-care, expanding access to new innovations that provide safe, effective and convenient symptom relief are more important than ever. "This milestone reinforces Reckitt's commitment to delivering trusted, science-backed solutions that meet everyday health needs and truly fit how Americans live," said Jérôme Lemaire, President, Reckitt North America. "By advan cing the cold and flu category with longer-lasting, 12-hour symptom relief, we are not just expanding consumer choice and access, we are easing the care burden on families and empowering people to stay focused on their daily lives." Cold and flu symptoms are largely driven by the body's inflammatory response to infection.3 Recognizing the role that inflammatory processes play in many cold and flu symptoms, Mucinex 12HR Cold & Fever Multi-Symptom was developed to provide long-lasting multi-symptom relief. As the first product in its category to combine guaifenesin, dextromethorphan HBr, and naproxen sodium—an NSAID (non-steroidal anti-inflammatory drug)—in a bilayer tablet, it delivers immediate and extended release of active ingredients providing symptom relief that lasts up to three times longer than most cold and flu medications.** "True innovation starts with understanding consumer needs and applying science to solve them," said Angela Naef, Ph.D., Chief R&D Officer, Reckitt. "This approval is the culmination of more than a decade of research and development to create a first-of-its-kind formulation that delivers long-lasting relief from multiple cold and flu symptoms." About Mucinex 12HR Cold & Fever Multi-Symptom Mucinex 12HR Cold & Fever Multi-Symptom is a first-of-its kind OTC medication designed to address the #1 unmet need in the cold and flu category—long-lasting symptom relief*—delivering up to 12 hours of relief in just one dose. Featuring a patented bi-layer tablet, Mucinex 12HR Cold & Fever Multi-Symptom combines three active ingredients for effective and convenient symptom relief: guaifenesin (expectorant), dextromethorphan HBr (cough suppressant), and naproxen sodium (NSAID for fever and pain). Reckitt launched Mucinex 12HR Cold & Fever Multi-Symptom in 2026, expanding the brand's portfolio of 12-hour products that consumers have trusted for more than 20 years to thin and loosen excess mucus, relieve chest congestion, and control coughing. Backed by more than a decade of scientific research and development, this milestone innovation reflects Reckitt's commitment to advancing science-backed solutions that address meaningful needs in the cold and flu category. About Reckitt We make the products people trust to care for the ones they love. We are home to some of the world's best-loved consumer health and hygiene brands, including Dettol, Durex, Finish, Gaviscon, Harpic, Lysol, Mucinex, Nurofen, Strepsils, Vanish and Veet. Consumers are at the heart of everything we do. By creating innovative, science-backed solutions, we support people every day to live healthier lives. Reckitt exists to protect, heal and nurture in the pursuit of a cleaner, healthier world. This commitment goes beyond the products we make. Through our actions, we expand access to healthcare, education and economic opportunities. We support the planet by reducing waste, conserving resources and driving sustainable innovation. We believe good health starts at home. With every action we take, we strive to make our consumers' lives easier, cleaner and healthier, to strengthen communities and to create a more sustainable future. Find out more or get in touch with us at Reckitt.com/us. Reckitt is the trading name of the Reckitt group of companies *Clear C&F U&A 2022 ** Compared to 1 dose of 4-hour medicine without re-dosing. References 1 U.S. Food and Drug Administration. (2026). Drugs@FDA: FDA-Approved Drugs: Mucinex® 12HR Cold & Fever Multi-Symptom, New Drug Application approval. 2 Centers for Disease Control and Prevention. (2026, July). Vital Statistics Rapid Release, Report No. 44: Mortality in the United States, Provisional Data, 2025. National Center for Health Statistics. 3 Eccles R. Understanding the symptoms of the common cold and influenza. Lancet Infect Dis 2005 Nov;5(11):718–25 Media Contact: Jen O'Neill Reckitt (U.S) [email protected] Will Hill Reckitt (UK) media&[email protected] SOURCE Reckitt 21% more press release views with Request a Demo

索引号XZXK-2026-10113主题分类工作动态标题国家药监局公布4起药品经营环节“清源”行动违法违规典型案例 发布日期 2026-06-16　　各级药品监督管理部门深入贯彻落实党中央、国务院有关决策部署，深入开展药品经营环节“清源”行动，持续加强药品网络销售监管，严厉打击违法违规行为，切实保障人民群众身体健康和用药安全。现将药品网络销售违法违规典型案例公布如下：　　一、四川杏林医药连锁有限责任公司广元市河阳路药店通过网络销售禁售药品案　　四川杏林医药连锁有限责任公司广元市河阳路药店通过微信小程序销售网络禁售药品。该药店上述行为违反了《药品网络销售监督管理办法》第八条规定。2025年4月，广元市利州区市场监督管理局依据《药品网络销售监督管理办法》第三十三条规定，责令该药店限期改正，并处罚款。　　二、大连捷晖企业管理有限公司无证经营药品案　　大连捷晖企业管理有限公司在未取得《药品经营许可证》的情况下，通过“快手小店”销售药品。该公司上述行为违反了《中华人民共和国药品管理法》第五十一条的规定。2025年6月，大连市金普新区市场监督管理局依据《中华人民共和国药品管理法》第一百一十五条、《辽宁省药品监督管理行政处罚裁量权适用规定》第十一条规定，责令该公司改正上述违法行为，给予没收违法所得并处罚款的行政处罚。　　三、荆门市金宏医药科技有限公司从非法渠道购进药品案　　荆门市金宏医药科技有限公司通过微信从个人处购进药品，属于未按规定渠道购进药品行为。该公司上述行为违反了《中华人民共和国药品管理法》第五十五条、第五十七条规定。2025年5月，荆门市市场监督管理局依据《中华人民共和国药品管理法》第一百二十九条、第一百三十条规定，给予警告、没收违法所得并处罚款的行政处罚。　　四、遂宁市安居区益康缘博海药店通过网络从无经营资格的企业购进药品案　　遂宁市安居区益康缘博海药店以个人名义通过网络从无药品批发经营资格的企业购进药品，且现场发现其他未遵守《药品经营质量管理规范》的行为。该药店上述行为违反了《中华人民共和国药品管理法》第五十三条、第五十五条规定。2025年11月，遂宁市安居区市场监督管理局依据《中华人民共和国药品管理法》第一百二十六条、第一百二十九条规定，责令该药店改正上述违法行为，给予警告、没收违法所得并处罚款的行政处罚。       消费与合规提示：　　消费者通过网络购买药品时，请关注两个资质：一是药品零售企业资质，网站首页或者经营活动的主页面显著位置是否公示《药品经营许可证》；二是药品资质，所购买药品是否取得国家药品监督管理局核发的《药品注册证书》。请勿通过社交软件、短视频直播平台等非正规渠道，从无资质的商家或者个人处购买药品。　　疫苗、血液制品、麻醉药品、精神药品、医疗用毒性药品、放射性药品、药品类易制毒化学品等国家实行特殊管理的药品不得在网络上销售，具体目录详见《国家药监局关于发布药品网络销售禁止清单（第一版）的公告》。国家药品监督管理局、公安部、国家禁毒委员会办公室联合发布通告，禁止通过网络零售或者变相零售普瑞巴林口服单方制剂、愈美制剂（仅含有右美沙芬和愈创甘油醚/愈创木酚甘油醚的制剂）。　　消费者如发现无资质网售药品、销售禁止网售药品等违法违规行为，请及时向所在地药品监督管理部门投诉举报。